drugset / Trial / NCT01736410
A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To explore overall response rate of trastuzumab combined with TS-ONE based chemotherapy in first-line HER2-positive advanced gastric cancer.
Timeline
- Start
- 2010-05
- Primary completion
- 2013-04
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | TS-ONE | Unknown | — | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |